ArticlemedRxiv : the preprint server for health sciences2025
Prognostic significance of natriuretic peptides after transcatheter aortic valve replacement: A systematic review and meta-analysis.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background—: Elevated B-type- and NT-pro-beta natriuretic peptide (BNP and NT-pro-BNP) after transcatheter aortic valve replacement (TAVR) may be associated with worse outcomes. Objective—: We performed a systematic review and meta-analysis to investigate the association of post-TAVR BNP and NT-pro BNP levels on all-cause mortality and heart failure hospitalization. Methods—: Seven retrospective studies (n=4143) were included, with a mean follow-up of 32 months. Lower BNP and NT-pro BNP was defined as BNP <202 pg/mL or NT-pro BNP <1423 pg/mL, or BNP that decreased >40% or NT-pro BNP decreased >30% from baseline, or pre/post-TAVR BNP or NT-pro BNP ratio ≥1. Higher BNP and NT-pro BNP was defined as BNP >202 pg/mL or NT-pro BNP >35,000 pg/mL or BNP decreased ≤40% or pre/post-TAVR ratio ≤1 or NT-pro BNP decreased ≤30% from baseline or pre/post-procedure NT-pro BNP ratio < 1. Results—: The mean age was 80 ±6 years in the lower group (n=2578) and 81 ±6 years in the higher group (n=1565). Higher BNP and NT-pro BNP persisting after TAVR were associated with a statistically significant increase in all-cause mortality (HR 2.85 [95% CI 2.15-3.78], p<0.00001) and heart failure hospitalization (HR 4.72 [95% CI 2.94-7.57], p<0.00001). A smaller difference between baseline and post-TAVR BNP and NT-pro BNP was associated with a statistically significant increase in all-cause mortality (HR 2.70 [95% CI 1.87-3.92], p<0.00001). Conclusion—: Individuals with higher natriuretic peptide levels after TAVR have higher hazards of all-cause mortality and heart failure hospitalization when compared with patients having lower post-procedural levels. Natriuretic peptides measured post-TAVR improve risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.